William Blair Remains a Buy on Taysha Gene Therapies (TSHA)

William Blair analyst Raju Prasad maintained a Buy rating on Taysha Gene Therapies (TSHAResearch Report) today. The company’s shares closed last Wednesday at $25.24.

According to TipRanks.com, Prasad is a 5-star analyst with an average return of 24.7% and a 61.3% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Alexion Pharmaceuticals, and Crispr Therapeutics AG.

Currently, the analyst consensus on Taysha Gene Therapies is a Moderate Buy with an average price target of $42.00.

See today’s analyst top recommended stocks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.